Immunomodulators Market Size To Reach $329.8 Million By 2030

Immunomodulators Market Growth & Trends

The global immunomodulators market size is expected to reach USD 329.8 million by 2030, expanding at a CAGR of 6.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is anticipated to be predominantly driven by high R&D investments employed by prominent companies, resulting in the large-scale production of new and therapeutically advanced drugs. This is believed to widen the influx of drugs at an unprecedented rate into the immunomodulators market hence providing highly efficacious treatment alternatives for numerous autoimmune and inflammatory diseases.

In addition, increasing drug resistance is predicted to be responsible for boosting the clinical urgency to develop potentially new generation immunomodulators with targeted therapy mechanisms. The aforementioned factors cumulatively are expected to present significant growth opportunities over the forecast period.

Furthermore, the burgeoning presence of the key players is expected to promote the awareness levels pertaining to the benefits of immunomodulators amongst the patients as well as the physicians. This is further expected to widen the immunomodulators industry growth potential during the forecast period.

In addition, increasing adoption of monoclonal antibodies for a wide range of indications, such as, multiple sclerosis, Crohn’s disease, rheumatoid arthritis, and Non-Hodgkin’s Lymphoma, which is expected to boost immunomodulators industry over the forecast period. The consistent number of product approvals of highly significant monoclonal antibodies in autoimmune diseases is predicted to be responsible for widening the scope of growth.

 Request a free sample copy or view report summary: Immunomodulators Market Report

Immunomodulators Market Report Highlights

• Immunosuppressant held the largest share of the product segment in 2023, owing to the increasing number of transplantation procedures and need to prevent organ rejection

• Antibodies held the dominant share of immunosuppressant in 2023, owing to extensive utilization in kidney, liver, heart, and lung transplants resulting in greater revenue generation

• Immunostimulants expected to grow lucratively as a result of the lower influx of immunostimulant generics for application in HIV, cancer and multiple sclerosis

• In 2023, North America dominated the global immunomodulators market owing to the presence of a wide number of established pharmaceutical companies involved in extensive commercialization

• The prominent participants are undertaking research and clinical collaborative strategies to yield new drugs and thereby to gain competitive advantage

• For instance, In March 2024, Ability Biologics concluded its seed funding, securing a total of USD 18 million in investment. This capital is expected to be directed towards the development of innovative and highly targeted immunomodulators.

Immunomodulators Market Segmentation

Grand View Research has segmented the global immunomodulators market based on product, application, and region:

Immunomodulators Product Outlook (Revenue, USD Million, 2018 - 2030)

• Immunosuppressants

• Immunostimulants

Immunomodulators Application Outlook (Revenue, USD Million, 2018 - 2030)

• Oncology

• Respiratory

• HIV

• Others

Immunomodulators Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • Saudi Arabia

  • UAE

  • South Africa

  • Kuwait

List of Key Players in Immunomodulators Market

• F. Hoffmann-La Roche Ltd

• Amgen Inc.

• Abbott.

• Johnson & Johnson Services, Inc.

• Novartis AG

• Eli Lilly and Company

• Bristol-Myers Squibb Company

• Merck & Co., Inc.

• Biogen

• Pfizer Inc.